Genetics in familial hypercholesterolaemia – from genetic research to new guidelines
AbstractFamilial Hypercholesterolaemia (FH) is genetic disorder touching up to 1 to 250 people, increasing the risk of atherosclerotic cardiovascular disease risk and early death by 3-13 times. The majority of mutations are autosomal dominant among 3 genes related to cholesterole metabolism: LDL-receptor (LDLR), apolipoprotein B (APOB) or proprotein convertase subtilisin/kexin type 9 (PCSK9). It comprises 60% of reported cases, which still is not at satisfactory level. This article summarizes new research in the field of FH and points out new therapeutic methods - PCSK9 inhibitors as advised in new European Society of Cardiology guidelines od dyslipidaemias.
Haralambos K, Whatley SD, Edwards R, et al. Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales, Atherosclerosis, Volume 240, Issue 1, 2015, Pages 190-196, ISSN 0021-9150, http://dx.doi.org/10.1016/j.atherosclerosis.2015.03.003.
Futema M, Shah S, Cooper JA, et al. Refinement of Variant Selection for the LDL Cholesterol Genetic Risk Score in the Diagnosis of the Polygenic Form of Clinical Familial Hypercholesterolemia and Replication in Samples from 6 Countries, Clin Chem 2015, 61 (1) 231-238; DOI: 10.1373/clinchem.2014.231365
Austin MA, Hutter CM, Zimmern RL, Humphries SE; Genetic Causes of Monogenic Heterozygous Familial Hypercholesterolemia: A HuGE Prevalence Review. Am J Epidemiol 2004; 160 (5): 407-420. doi: 10.1093/aje/kwh236
Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG, et al., Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands, The Lancet, Volume 357, Issue 9251, 2001, Pages 165-168, ISSN 0140-6736, http://dx.doi.org/10.1016/S0140-6736(00)03587-X.
Al-Allaf FA, Athar M, Abduljaleel Z, et al., Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease, Gene, Volume 565, Issue 1, 1 July 2015, Pages 76-84, ISSN 0378-1119
Maglio C., Mancina R. M., Motta B. M., et al. Genetic diagnosis of familial hypercholesterolaemia by targeted next-generation sequencing. J Intern Med 2014; 276: 396–403.
Bourbon M, Alves AC, Alonso R, Nelva Mata, et al. Mutational analysis and genotype-phenotype relation in familial hypercholesterolemia: The SAFEHEART registry, Atherosclerosis, Volume 262, July 2017, Pages 8-13, ISSN 0021-9150, https://doi.org/10.1016/j.atherosclerosis.2017.04.002.
Catapano AL, Graham I, De Backer G, et al., 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 2016; 37 (39): 2999-3058. doi: 10.1093/eurheartj/ehw272
M. K. and Santos, R. D. (2017), PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia. The Journal of Clinical Pharmacology, 57: 7–32. doi:10.1002/jcph.766